Pulse Biosciences, Inc. (PLSE) Reports Q4 Loss of $0.51

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. LMT
8. USO
9. META
10. TLT

Go back to Pulse Biosciences, Inc. (PLSE) Reports Q4 Loss of $0.51

Pulse Biosciences Quarterly Investor Conference Call

February 7, 2019 4:01 PM EST

First patient treated in the CellFX back acne clinical feasibility study

Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel medical therapy company bringing to market its proprietary CellFX System, today reported recent corporate developments, and financial results for the quarter and year-ended December 31, 2018.

The Company also announced today treatment of the first of up to 20 patients in a clinical feasibility study to evaluate the CellFX... More